Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19

Autor:	Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Favipiravir Marketing authorization law.invention Clinical trial Randomized controlled trial law RNA Polymerase Inhibitor Internal medicine Interim Medicine Christian ministry business
DOI:	10.1101/2020.07.26.20154724
Popis:	In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5 Zobrazit plný text záznamu